Diagnostic value of sex hormone, prostate specific antigen and relevant parameters in prostate cancer
ＸU Hui1 WANG Zhiyong1 CHANG Hui1 WANG Zhenchao1 MA Guang1 MA Yinghui2
1.Department of Urology, the Affiliated Hospital of Chengde Medical College, Hebei Province, Chengde 067000, China;
2.Department of Ophthalmology, the Affiliated Hospital of Chengde Medical College, Hebei Province, Chengde 067000, China
Abstract：Objective To explore serum sex hormone T, FSH, LH, E2, P, PRL, PSA levels and evaluate the diagnostic value of the patients with prostate cancer (PCa). Methods 30 patients with PCa (PCa group), 45 cases of benign prostatic hyperplasia (BPH group) and 45 medical normal cases (control group) were selected to examine the six indicators of sex hormone(T, FSH, LH, E2, P, PRL) and PSA levels from the Affiliated Hospital of Chengde Medical College from October 2012 to December 2016. The diagnostic value of each parameter to detect PCa was assessed by the receiver operating characteristic (ROC) curve. Results Compared with the BPH group and control group, the serum T level in PCa group was significantly decreased, while FSH and LH were significantly increased (P < 0.05), E2, P, PRL levels were no significant differences (P > 0.05). Compared with the control group, the various sex hormone levels in BPH group were no significant differences (P > 0.05). Compared with the control group, the serum total PSA (TPSA), free PSA (FPSA) and PSA density (PSAD) in PCa group and BPH group were significantly increased, while F/T was significantly decreased (P < 0.05). Compared with the BPH group, the serum TPSA, FPSA and PSAD in patients with PCa group were significantly increased, while F/T was significantly decreased (P < 0.05). The areas under the ROC curves (AROC) of TPSA, FPSA, PSAD, T, FSH and LH were 1.000, 0.894, 0.991, 0.920, 0.753, 0.868. The testing parameters AROC comparison from big to small for TPSA, PSAD, T, FPSA, LH and FSH, differences between TPSA and PSAD, FPSA and T, FPSA and LH, PSAD and T, T and LH, FSH and LH were no statistically significance (P > 0.05). The remaining differences between paired were statistically significant (P < 0.05). Conclusion The serum T level in patients with PCa is decreased but FSH and LH levels are increased. The combined detection of sex hormone and serum PSA is a valuable early diagnostic tool for PCa．
徐辉1 王志勇1 常辉1 王振潮1 马光1 马英慧2. 性激素、前列腺特异性抗原及其相关参数对前列腺癌的诊断价值[J]. 中国医药导报, 2017, 14(15): 76-79.
ＸU Hui1 WANG Zhiyong1 CHANG Hui1 WANG Zhenchao1 MA Guang1 MA Yinghui2. Diagnostic value of sex hormone, prostate specific antigen and relevant parameters in prostate cancer. 中国医药导报, 2017, 14(15): 76-79.
[1] 王炜，李传刚，刘辉，等.前列腺特异性抗原对前列腺癌诊断价值的探讨[J].中国医科大学学报，2016，45（1）：61-65，69.
[2] 周敏卿，马玲.系统护理干预配合腹腔镜前列腺癌根治术的临床效果[J].中国医药导报，2016，13（20）：162-166.
[3] Godtman RA，Holmberg E，Lilja H，et al. Opportunistic testing versus organized prostate-specific antigen screening：outcome after 18 years in the G■teborg randomized population-based prostate cancer screening trial [J]. Eur Urol，2015，68（3）：354-360．
[4] 郭寻竹，宋丽萍.血清肿瘤标志物与前列腺癌骨转移程度的相关性研究[J].中国全科医学，2015，18（8）：903-905，910.
[5] 张华，钟白云，王新华，等.血清t-PSA及f-PSA/t-PSA联合诊断前列腺癌的价值评价[J].中国现代医学杂志，2014，24（7）：24-27.
[6] 柳东辉，王贻兵，李乐义，等.DRE、TRUS与MP-MRI在前列腺癌初筛诊断中的应用价值[J].中国医药导报，2016， 13（27）：91-94.
[7] 鲁克庆，吴茜，孙月，等.雌激素及其受体在前列腺癌中的作用[J].现代泌尿生殖肿瘤杂志，2015，7（3）：187-189.
[8] Levine AC，Ren M，Huber GK，et al. The effect of androgen，estorgen，and growth factors on the proliferation of cultured fibroblasts derived from human fetal and adult prostates [J]. Endocrinology，1992，130（4）：2413-2419.
[9] 孙伟桂，甘艺平，余强国，等.人前列腺癌LNCap与DUl45细胞的性激素、VEGF、bFGF和PSA等差异表达及其意义[J].中国男科学杂志，2008，22（11）：5-8，16.
[10] 黄诚刚，陈小艳，马春清，等.血清FPSA/TPSA及性腺激素测定结合核素骨显像在前列腺癌诊断、复发和转移中的临床价值[J].国际放射医学核医学杂志，2010， 34（6）：337-343.
[11] 张军，吕朝晖，母义明，等.前列腺癌患者性激素与促性腺激素的变化[J].中国实用内科杂志，2006，26（14）：1053-1055.
[12] Crevoisier RD，Slimane K，Messai T，et al. Early PSA decrease is an independent predictive factor of clinical failure and specific survival in patients with localized prostate cancer treated by radiotherapy with or without androgen deprivation therapy [J]. Ann Oncol，2010，2l（4）：808-814．
[13] 余明海，陈鹄，蒲军.PSA、PSAD和PSAT在前列腺穿刺活检中的价值[J].国际泌尿系统杂志，2017，37（1）：77-80.
[14] 吴杰，赵睿哲，黄源，等.PSA“灰区”前列腺癌预测模型及随访系统的建立[J].中华泌尿外科杂志，2016，37（4）：280-283.
[15] 李方龙，李德维，张一琰，等.预测前列腺穿刺阳性风险的列线图模型的建立[J].中华泌尿外科杂志，2016，37（8）：616-620.
[16] Kim YM，Park S，Kim J，et al. Role of prostate volume in the early detection of prostate cancer in a cohort with slowly increasing prostate specific antigen [J]. Yonsei Med J，2013，54（5）：1202-1206.
[17] 刘明，侯惠民，李欣，等.前列腺特异抗原异常患者的前列腺体积前列腺特异性抗原密度和游离前列腺特异抗原与总前列腺特异抗原比值在前列腺癌检出中的价值[J].中华肿瘤杂志，2016，38（7）：526-529.
[18] 马明辉，黄庆渡，高宇，等.f/t PSA、PSAD、（f/t）/PSAD在PSA 4～20 μg/L区间对前列腺癌的诊断预测价值[J].微创泌尿外科杂志，2015，4（6）：366-371.
[19] 丁勇生，夏淦林，王汉杰. Medcalc软件进行ROC曲线分析在影像学中的应用[J].临床医药实践，2011，20（4）：275-277.
[20] 吴沛珊，付宜鸣，冯堃，等.PSA相关指标对前列腺癌诊断价值的评价及比较研究[J].现代生物医学进展，2015， 15（2）：291-293.
2017, Vol. 14 
京公网安备 11010502046598号